

DAFTAR PUSTAKA

- Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Nist, A., Stiewe, T., Wagner, U., Müller-Brüsselbach, S., Reinartz, S. and Müller, R., 2017. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. *BMC genomics*, 18(1), p.243.
- Ahmed, N. dan Stenvers, K., 2013. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. *Frontiers in oncology*, 3, p.256.
- American Cancer Society. 2018. Ovarian Cancer. Atlanta: American Cancer Society, Inc. 2018. Didapat dari <https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html> diakses 20 Mei 2018
- Assem, H., Rambau, P.F., Lee, S., Ogilvie, T., Sienko, A., Kelemen, L.E. and Köbel, M., 2018. High-grade Endometrioid Carcinoma of the Ovary. *The American journal of surgical pathology*, 42(4), pp.534-544.
- Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M.L., Liakos, C., Tsitsilonis, O., Rodolakis, A., Voulgaris, Z., Vlahos, G., Papageorgiou, T. and Papatheodoridis, G., 2008. Correlation of NK T-like CD3+ CD56+ cells and CD4+ CD25+ (hi) regulatory T cells with VEGF and TNF α in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. *Gynecologic oncology*, 108(2), pp.421-427.
- Calle, E.E., Rodriguez, C., Walker-Thurmond, K. and Thun, M.J., 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. *New England Journal of Medicine*, 348(17), pp.1625-1638.
- Cancer Research UK. 2017. Cancer Grading. Didapat dari <https://www.cancerresearchuk.org/about-cancer/what-is-cancer/cancer-grading> diakses 20 Mei 2018
- Cândido, E.B., Silva, L.M., Carvalho, A.T., Lamaita, R.M., Filho, R.M.P., Cota, B.D.C.V. and Silva-Filho, A.L.D., 2013. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. *Reproductive Sciences*, 20(7), pp.828-837.
- Castro, F., Cardoso, A.P., Gonçalves, R.M., Serre, K. and Oliveira, M.J., 2018. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. *Frontiers in immunology*, 9, p.847.
- Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L. and Cheng, W.F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PloS one*, 13(3), p.e0194993.
- Chen, Y.L., Cheng, W.F., Chang, M.C., Lin, H.W., Huang, C.T., Chien, C.L. and Chen, C.A., 2013. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. *Gynecologic oncology*, 131(1), pp.63-68.
- Cohen, M. dan Petignat, P., 2014. The bright side of ascites in ovarian cancer. p 2319.

- Coosemans, A., Decoene, J., Baert, T., Laenen, A., Kasran, A., Verschuere, T., Seys, S. and Vergote, I., 2016. Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. *Oncoimmunology*, 5(4), p.e1111505.
- Duncan, T.J., Rolland, P., Deen, S., Scott, I.V., Liu, D.T., Spendlove, I. and Durrant, L.G., 2007. Loss of IFN γ receptor is an independent prognostic factor in ovarian cancer. *Clinical cancer research*, 13(14), pp.4139-4145.
- Ezzati, M., Abdullah, A., Sharifabrizi, A., Hou, J., Kopf, M., Stedman, J.K., Samuelson, R. and Shahabi, S., 2014. Recent advancements in prognostic factors of epithelial ovarian carcinoma. *International scholarly research notices*, 2014.
- Hosono, S., Kajiyama, H., Mizuno, K., Sakakibara, K., Matsuzawa, K., Takeda, A., Kawai, M., Nagasaka, T. and Kikkawa, F., 2011. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. *International journal of clinical oncology*, 16(5), p.524.
- Kementerian Kesehatan RI. 2015. Pusat Data dan Informasi. Jakarta.
- Kim, S., Kim, B. and Song, Y.S., 2016. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. *Cancer science*, 107(9), pp.1173-1178.
- Lee, S. and Margolin, K., 2011. Cytokines in cancer immunotherapy. *Cancers*, 3(4), pp.3856-3893.
- Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T. and Konishi, I., 2016. Dual faces of IFN γ in cancer progression: a role of PD-L1 induction in the determination of pro-and antitumor immunity. *Clinical Cancer Research*, 22(10), pp.2329-2334.
- Mardiah, A. & Lubis, N.D., 2015. Ekspresi IFN- γ dan IL -4 pada Tumor Jinak dan Ganas Epitelial Ovarium Jenis Serosum dan Musinosum. *Majalah Patologi*, 24(1), pp.35-41.
- Marth, C., Fiegl, H., Zeimet, A.G., Müller-Holzner, E., Deibl, M., Doppler, W. and Daxenbichler, G., 2004. Interferon- γ expression is an independent prognostic factor in ovarian cancer. *American journal of obstetrics and gynecology*, 191(5), pp.1598-1605.
- Mojic, M., Takeda, K. and Hayakawa, Y., 2017. The dark side of IFN- γ : its role in promoting cancer immunoevasion. *International journal of molecular sciences*, 19(1), p.89.
- Nagle, C.M., Dixon, S.C., Jensen, A., Kjaer, S.K., Modugno, F., Fereday, S., Hung, J., Johnatty, S.E., Fasching, P.A., Beckmann, M.W. and Lambrechts, D., 2015. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *British journal of cancer*, 113(5), p.817.
- Nowak, M., Glowacka, E., Szpakowski, M., Szylo, K., Malinowski, A., Kulig, A., Tchorzewski, H. and Wilczynski, J., 2010. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. *Neuroendocrinology Letters*, 31(3), pp.375-383.

- Prat, J. and FIGO Committee on Gynecologic Oncology, 2015. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. *Journal of gynecologic oncology*, 26(2), pp.87-89.
- Reid, B.M., Permeth, J.B. and Sellers, T.A., 2017. Epidemiology of ovarian cancer: a review. *Cancer biology & medicine*, 14(1), p.9.
- Ricci, F., Affatato, R., Carrassa, L. and Damia, G., 2018. Recent insights into mucinous ovarian carcinoma. *International journal of molecular sciences*, 19(6), p.1569.
- Tian, Q., Lu, B., Ye, J., Lu, W., Xie, X. and Wang, X., 2016. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma. *Journal of International Medical Research*, 44(2), pp.357-366.
- Union for International Cancer Control (UICC). 2016. TNM Classification of Malignant Tumours-8th edition.
- Webb, P.M. and Jordan, S.J., 2017. Epidemiology of epithelial ovarian cancer. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 41, pp.3-14.
- Winter, W.E., Maxwell, G.L., Tian, C., Carlson, J.W., Ozols, R.F., Rose, P.G., Markman, M., Armstrong, D.K., Muggia, F. and McGuire, W.P., 2007. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. *Journal of Clinical Oncology*, 25(24), pp.3621-3627.
- World Health Organization. 2014. Cancer Country Profile: Indonesia. Didapat dari https://www.who.int/cancer/country-profiles/idn_en.pdf diakses 28 Desember 2018
- World Health Organization. 2014. WHO Classification of Tumors of Female Reproductive Organs. 4th Edition. pp 15-40.
- Zaidi, M.R. dan Merlino, G., 2011. The two faces of interferon- γ in cancer. *Clinical cancer research*, 17(19), pp.6118-6124.